✨ Medicine Consents




17 AUGUST NEW ZEALAND GAZETTE 2269

Product:
Active Ingredient(s):
Doxorubicin
Dosage Form:
Solution for injection
New Zealand Sponsor:
Hexal New Zealand Pty Limited
Manufacturer(s):
Ebewe Arzneimittel GmbH, Unterach, Austria

Doxorubicin Hexal
Doxorubicin hydrochloride 2mg/mL

Product:
Active Ingredient(s):
Disodium etidronate
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Genpharm Inc., Pharmaceuticals, Etobicoke, Ontario, Canada

Etidrate
Disodium etidronate 200mg

Product:
Active Ingredient(s):
Disodium etidronate
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Genpharm Inc., Pharmaceuticals, Etobicoke, Ontario, Canada

Etidrate
Disodium etidronate 400mg

Product:
Active Ingredient(s):
Alcohol 22.5%v/v
Benzoic acid 0.105%w/v
Cineole 0.092%w/v
Thymol 0.064%w/v
Zinc chloride 0.09%w/v
Dosage Form:
Mouthwash
New Zealand Sponsor:
Warner-Lambert Consumer Healthcare Pty Limited
Manufacturer(s):
Parke Davis Pty Limited, Caringbah, Sydney, New South Wales, Australia

Listerine Tartar Control Antiseptic Mouthwash

Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany

Psyxitoxol Injection
Flupenthixol decanoate 100mg/mL

Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany

Psyxitoxol Injection
Flupenthixol decanoate 200mg/mL

Product:
Active Ingredient(s):
Flupenthixol decanoate
Dosage Form:
Injection (depot)
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer(s):
Merck KGaA, Darmstadt, Germany

Psyxitoxol
Flupenthixol decanoate 20mg/mL

Dated this 9th day of August 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go5953

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product:
Hivid
Active Ingredient(s):
Zalcitabine 0.75mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturer(s):
Hoffmann-La Roche Inc, Nutley, New Jersey, United States of America

Note: This consent is valid for 2 years from 17 December 2000.

Dated this 9th day of August 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go5955



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2000, No 92


Gazette.govt.nz PDF NZ Gazette 2000, No 92





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
9 August 2000
Medicines Act 1981, New Medicine Distribution, Doxorubicin, Etidrate, Listerine, Psyxitoxol
  • G. R. Boyd, Chief Advisor, Safety and Regulation

πŸ₯ Renewal of Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
9 August 2000
Medicines Act 1981, New Medicine Distribution, Hivid, Zalcitabine
  • G. R. Boyd, Chief Advisor, Safety and Regulation